Home » Newsletters » BioWorld

BioWorld

March 26, 1992

View Archived Issues

CHEMIX REVERSE STOCK SPLIT

EVANS-FREKE VENTURE RAISES $6M

CELLPRO ADDS NEW CEPRATE KITS

CORVAS SBIR FOR DRUG DESIGN STUDY

DNAP TO TRIPLE JOINT VENTURE REVENUE

ANOTHER IPO SUFFERS IN SOFT MARKET

PHASE III BEGINS ON ELECTRIC SHOCK ADJUNCT

MERGING COMPANIES LINE UP ANOTHER DEAL

BAXTER BUYS STAKE IN AIDS VACCINE DEVELOPER

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...